The National Cancer Institute is sponsoring a one-year clinical trial set to begin later this year of a Dimericine, a topical liposomal DNA repair enzyme, to see if it is effective in reducing the rate of skin cancer in kidney transplant recipients.

Kidney transplant recipients tend to be more prone to develop skin cancer from exposure to the sun because of their need to take daily immunosuppressive medications.

The trial will be conducted at the University of Alabama at Birmingham and possibly as many as three other sites around the country, according to Daniel B. Yarosh, president of Applied Genetics Inc.

Other sources: Appied Genetics